Research map: Real-World Safety and Effectiveness of Neoadjuvant Chemoimmunotherapy in Squamous Cell Lung Cancer: A Retrospective European Multicentre Study

Back to the article

Papers in this map

  1. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer · Patrick M. Forde · 2022 · 2741 citations · Cited by this paper
  2. Poor Performance Status Associated With Inferior Tarlatamab Outcomes in a Large, Multi-institution Real-World Database of Patients With 2L + ES-SCLC · 2026 · Related
  3. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group · Jean‐Pierre Pignon · 2008 · 2707 citations · Cited by this paper
  4. Next-Generation Sequencing Completion and Timeliness Using a Reflex Testing Protocol for Patients with Stage II to IV Nonsquamous Non–Small Cell Lung Cancer · 2026 · Related
  5. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer · Heather A. Wakelee · 2023 · 1148 citations · Cited by this paper
  6. Brief Report: A Pilot Study Evaluating the Feasibility, Safety, and Compliance With a Fasting-Mimicking Diet in Patients With Metastatic Non–Small Cell Lung Cancer · 2026 · Related
  7. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial · Mariano Provencio · 2020 · 855 citations · Cited by this paper
  8. Complete Spontaneous Regression of Lung Adenocarcinoma With No Residual Malignancy After Surgical Resection: A Case Report · 2026 · Related
  9. Perioperative Nivolumab in Resectable Lung Cancer · Tina Cascone · 2024 · 517 citations · Cited by this paper
  10. Clinicogenomic Predictors of First-line Immune Checkpoint Inhibitor Outcomes in Non–Small Cell Lung Cancer: A Nationwide C CAT Cohort From Japan · 2026 · Related
  11. Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer · Mariano Provencio · 2023 · 483 citations · Cited by this paper
  12. Streamlining the Frequency, Conduct, and Location of Assessments in Registrational Lung Cancer Clinical Trials for Supplemental Applications: Recommendations of a LUNGevity Foundation Multistakeholder Working Group · 2026 · Related
  13. A proteogenomic portrait of lung squamous cell carcinoma · Shankha Satpathy · 2021 · 404 citations · Cited by this paper
  14. Impact of Programmed Death Ligand 1 Expression on Outcomes in Stage I-II Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma · 2026 · Related
  15. Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer · Patrick M. Forde · 2025 · 236 citations · Cited by this paper
  16. Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer: Outcomes Based on Completeness of Consolidation and Oligometastatic State · 2026 · Related
  17. Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study · Ganfeng Luo · 2025 · 153 citations · Cited by this paper
  18. Adjuvant Therapy After Pathologic Complete Response to Neoadjuvant Immunochemotherapy in Non–Small Cell Lung Cancer: A Multicenter Retrospective Real-World Study · 2026 · Related
  19. Updated treatment recommendations for systemic treatment: from the ESMO non-oncogene-addicted metastatic NSCLC Living Guideline · Lizza E.L. Hendriks · 2025 · 19 citations · Cited by this paper
  20. Dosimetric Predictors of Radiation Pneumonitis for Stage III NSCLC Treated With Neoadjuvant Immuno-chemotherapy and Definitive Chemoradiation: A Multi-institutional Analysis · 2026 · Related
  21. Untitled · Cited by this paper
  22. Untitled · Cited by this paper

Source: OpenAlex (CC0)